Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 75/100

Termination Rate

14.3%

1 terminated out of 7 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

6Total
P 1 (3)
P 2 (2)
P 3 (1)

Trial Status

Not Yet Recruiting3
Recruiting3
Terminated1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07705334Phase 1Recruiting

A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors

NCT07029399Phase 1RecruitingPrimary

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

NCT07307287Phase 2Not Yet Recruiting

SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study

NCT06787118Phase 3Not Yet Recruiting

Study Assessing the Efficacy and Safety of cANnabidiol Oral Solution for Joint Pain of Adjuvant enDOcrine theRApy in Patients With Early Breast Cancer

NCT05252416Phase 1Terminated

(VELA) Study of BLU-222 in Advanced Solid Tumors

NCT07080619Phase 2Not Yet Recruiting

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

NCT06734533RecruitingPrimary

Anlotinib-based Combination Therapy in Patients with Hormone Receptor-positive（HR+） Metastatic Breast Cancer(MBC) .

Showing all 7 trials

Research Network

Activity Timeline